{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T15:56:08Z","timestamp":1792252568674,"version":"4.4.0"},"reference-count":21,"publisher":"American Society of Clinical Oncology (ASCO)","issue":"23","content-domain":{"domain":["ascopubs.org"],"crossmark-restriction":true},"short-container-title":["JCO"],"published-print":{"date-parts":[[2024,8,10]]},"abstract":"<jats:sec>\n                    <jats:title>PURPOSE<\/jats:title>\n                    <jats:p>Leptomeningeal metastases (LMs) exhibit a high incidence in patients with epidermal growth factor receptor (EGFR)\u2013mutated non\u2013small cell lung cancer (NSCLC) post-treatment with first- or second-generation EGFR tyrosine kinase inhibitors (TKIs). This investigation evaluates the efficacy, safety, and pharmacokinetics of 80 mg once daily osimertinib in patients with LMs resistant to prior first- or second-generation EGFR TKIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>MATERIALS AND METHODS<\/jats:title>\n                    <jats:p>In this phase II multicenter, open-label, single-arm study, 80 mg osimertinib was administered to patients with EGFR-mutated NSCLC who had developed LMs subsequent to treatment with prior EGFR TKIs. The primary end point was overall survival (OS), assessed alongside objective response rate by the blinded independent central review (BICR) and a pharmacokinetic analysis of plasma and cerebrospinal fluid (CSF) on the first day of cycles 3 and 6.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>A total of 73 patients diagnosed with LM were treated with osimertinib, including 64 patients evaluable for the LM efficacy set\u2014T790M negative (n = 62) and T790M positive (n = 2). The median OS in the full-analysis set was 15.6 months (95% CI, 11.5 to 20.2). The objective response rate for LM was 51.6%, including a 15.6% complete response, and the disease control rate was 81.3% by BICR in the LM efficacy evaluable set. The median LM progression-free survival by BICR was 11.2 months (95% CI, 7.7 to 15.3), the duration of response was 12.6 months (95% CI, 7.6 to 17.7), and OS was 15.0 months (95% CI, 11.3 to 18.7). Pharmacokinetic analysis showed that the CSF to free plasma osimertinib ratio was 22%. Most safety profiles were grade 1 and 2.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSION<\/jats:title>\n                    <jats:p>The study demonstrates significant intracranial efficacy and survival benefits of 80 mg once daily osimertinib in NSCLC patients with LMs. The data support considering daily 80 mg of osimertinib as a treatment option for EGFR-mutated NSCLC patients with LMs, irrespective of T790M mutation status.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1200\/jco.24.00708","type":"journal-article","created":{"date-parts":[[2024,6,3]],"date-time":"2024-06-03T07:59:21Z","timestamp":1717401561000},"page":"2747-2756","update-policy":"https:\/\/doi.org\/10.1200\/crossmark","source":"Crossref","is-referenced-by-count":64,"title":["Phase II Efficacy and Safety of 80 mg Osimertinib in Patients With Leptomeningeal Metastases Associated With Epidermal Growth Factor Receptor Mutation\u2013Positive Non\u2013Small Cell Lung Cancer (BLOSSOM)"],"prefix":"10.1200","volume":"42","clinical-trial-number":[{"clinical-trial-number":"nct04563871","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9467-461X","authenticated-orcid":false,"given":"Sehhoon","family":"Park","sequence":"first","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0525-1119","authenticated-orcid":false,"given":"Richard","family":"Baldry","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology and Quantitative Pharmacology, Post Market and Lifecycle Management, AstraZeneca, Cambridge, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1583-4142","authenticated-orcid":false,"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1800-5881","authenticated-orcid":false,"given":"Jong-Mu","family":"Sun","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9219-3350","authenticated-orcid":false,"given":"Se-Hoon","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2880-6730","authenticated-orcid":false,"given":"Jin Seok","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5037-0523","authenticated-orcid":false,"given":"Yu Jung","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Department of Internal Medicine, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0180-189X","authenticated-orcid":false,"given":"Youngjoo","family":"Lee","sequence":"additional","affiliation":[{"name":"Center for Lung Cancer, Research Institute and Hospital, National Cancer Center, Goyang-si Gyeonggi-do, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5124-7132","authenticated-orcid":false,"given":"Dong-Wan","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-We","family":"Kim","sequence":"additional","affiliation":[{"name":"Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7830-5950","authenticated-orcid":false,"given":"Ki Hyeong","family":"Lee","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0653-8568","authenticated-orcid":false,"given":"Won Jae","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Tumor Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Won","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Tumor Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2501-0400","authenticated-orcid":false,"given":"Kyuha","family":"Chong","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Tumor Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung-Il","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Neurosurgery, Brain Tumor Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6591-8291","authenticated-orcid":false,"given":"So-Hyeon","family":"Gwon","sequence":"additional","affiliation":[{"name":"Department of Statistics, Keimyung University, Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6192-8852","authenticated-orcid":false,"given":"Nak-Hoon","family":"Son","sequence":"additional","affiliation":[{"name":"Department of Statistics, Keimyung University, Daegu, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5740-9654","authenticated-orcid":false,"given":"Myung-Ju","family":"Ahn","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"233","reference":[{"key":"b1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2018.11.022"},{"key":"b2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2016.06.029"},{"key":"b3","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/neuonc\/nor121","volume":"13","author":"Grommes C","year":"2011","journal-title":"Neuro Oncol"},{"key":"b4","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1871"},{"key":"b5","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0399"},{"key":"b6","doi-asserted-by":"publisher","DOI":"10.1177\/0271678X19843776"},{"key":"b7","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02186"},{"key":"b8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.78.3118"},{"key":"b9","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00457"},{"key":"b10","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.06.017"},{"key":"b11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.06.018"},{"key":"b12","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.3223"},{"key":"b13","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30508-3"},{"key":"b14","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy425.022"},{"key":"b15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612674"},{"key":"b16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2019.12.113"},{"key":"b17","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/neuonc\/now197","volume":"19","author":"Chamberlain M","year":"2017","journal-title":"Neuro Oncol"},{"key":"b18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2008.10.026"},{"key":"b19","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913662"},{"key":"b20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2306434"},{"key":"b21","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.10.062"}],"container-title":["Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascopubs.org\/doi\/pdfdirect\/10.1200\/JCO.24.00708","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T18:00:35Z","timestamp":1723053635000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascopubs.org\/doi\/10.1200\/JCO.24.00708"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,10]]},"references-count":21,"journal-issue":{"issue":"23","published-print":{"date-parts":[[2024,8,10]]}},"alternative-id":["10.1200\/JCO.24.00708"],"URL":"https:\/\/doi.org\/10.1200\/jco.24.00708","relation":{},"ISSN":["0732-183X","1527-7755"],"issn-type":[{"value":"0732-183X","type":"print"},{"value":"1527-7755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,8,10]]},"assertion":[{"value":"2024-04-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-28","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-02","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-06-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}